Clinical Trial

Hepatocellular Carcinoma Imaging Using PSMA PET/CT

Study acronym: HepaSMART
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 16, 2025 (before its estimated March 8, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of the research is to evaluate the use of a PSMA PET/CT (Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography) scan in the diagnosis of HCC (hepatocellular carcinoma) and comparing it to standard scanning techniques with CT (Computed Tomography) or MRI (Magnetic Resonance Imaging).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-10-25; most recent amendment 2025-07-13.
Status change: Recruiting → Active, Not Recruiting 2025-07-13
Trial Details
NCT Number NCT05095519
Lead Sponsor Peter MacCallum Cancer Centre, Australia
Conditions Hepatocellular Carcinoma
Enrollment 30 participants
Start Date 2021-09-08
Primary Completion 2026-03-08 (estimated)
Study Completion 2026-09-08 (estimated)
Updated on ClinicalTrials.gov 2025-07-16